ConvaTec Group (LON:CTEC)‘s stock had its “hold” rating reiterated by equities research analysts at Peel Hunt in a research note issued on Wednesday.
Several other equities research analysts have also recently issued reports on CTEC. Numis Securities reissued a “reduce” rating and issued a GBX 180 ($2.53) price objective on shares of ConvaTec Group in a research report on Tuesday, December 5th. Citigroup reissued a “neutral” rating and issued a GBX 226 ($3.17) price objective on shares of ConvaTec Group in a research report on Friday, February 16th. Credit Suisse Group lowered their price objective on shares of ConvaTec Group from GBX 225 ($3.16) to GBX 215 ($3.02) and set a “neutral” rating for the company in a research report on Thursday, February 15th. Morgan Stanley reissued an “overweight” rating and issued a GBX 249 ($3.50) price objective on shares of ConvaTec Group in a research report on Friday, February 23rd. Finally, Royal Bank of Canada raised shares of ConvaTec Group to an “outperform” rating and lowered their price objective for the company from GBX 260 ($3.65) to GBX 240 ($3.37) in a research report on Thursday, March 22nd. One analyst has rated the stock with a sell rating, five have given a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of GBX 237.36 ($3.33).
ConvaTec Group stock opened at GBX 201.80 ($2.83) on Wednesday. ConvaTec Group has a 1 year low of GBX 181.40 ($2.55) and a 1 year high of GBX 349.10 ($4.90).
ConvaTec Group Plc is a medical product and technology company. The Company focuses on therapies for the management of chronic conditions, including products used for advanced chronic and acute wound care, ostomy care, continence and critical care and infusion devices used in the treatment of diabetes and other conditions.
Receive News & Ratings for ConvaTec Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConvaTec Group and related companies with MarketBeat.com's FREE daily email newsletter.